Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
July 06, 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, July 06, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI...
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
June 21, 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer...
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
February 22, 2022 07:15 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) +...
Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment
November 15, 2021 09:55 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of...
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study
September 21, 2021 08:00 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) and Newsoara BioPharma Co., Ltd. (“Newsoara”) announced today the initiation of a...